BioMarin Announces Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $80 at Oppenheimer
October 24, 2019 7:02 AM EDTOppenheimer analyst Leland Gershell lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $80.00 (from $81.00) while maintaining a Perform rating.
The analyst commented, "BMRN's 3Q19 total product revenue of $451M was roughly in line with consensus of $448M, with lower R&D... More
BioMarin Pharma (BMRN) Tops Q3 Revenue
October 23, 2019 4:16 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of $0.30, which may not compare to the analyst estimate of $0.06. Revenue for the quarter came in at $461.1 million versus the consensus estimate of $454.55 million.
Commenting on third quarter results, Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, said, "BioMarin is entering a stage that I believe will bring significant growth as we get closer to submitting marketing applications for valoctocogene roxaparvovec for severe hemophilia A and a pivotal data read-out for vosoritide for children with achondroplasia. These potential new products, combined with our strong base business... More
